We are now moving into the MANUFACTURING STAGE, going through the pre-launch regulatory processes and distributors have been identified. If you want to be part of this journey or to discuss a proposed investment, please contact us. The commercial opportunities are substantial and the clinical benefits to patients could be life changing. As evidence mounts of the substantial risks to patients produced by the oral delivery of medicines to combat bladder conditions UroPharma has

UroPharma’s dtb-Instilla Intermittent will: aid the fight against anti-microbial resistance, Urinary Tract Infections and address the serious damage inflicted on the gut microbiome by the oral delivery of antibiotics. help to limit the massively increased risk of developing dementia caused by the oral delivery of anticholinergics to treat common bladder problems that cause suffering for millions worldwide. On receipt of regulatory approval, UroPharma’s combined drainage and d

Quality of Life is a priority for healthcare professionals. Direct-to-Bladder therapies by UroPharma go a long way towards achieving best clinical practices as set out below. Accurate dose, Direct to target, Immediate action, confined to the bladder: the right dose, in the right place, at the right time.

About UroPharma UroPharma has patented and developed the world’s first licensed ‘direct to bladder’ drug delivery system, that will be in the market by early 2023. This overcomes clinical limitations and significant harms caused by the oral delivery of drugs intended for bladder therapy. The design incorporates safety features intended to reduce costs associated with treating catheter acquired urinary tract infections caused by antibiotic resistance. Urinary tract infections